CAD106

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
012320102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
INTRODUCTION This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity… (More)
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2015
Review
2015
Active or passive immunotherapy is expected to slow or stop the pathological process of Alzheimer's disease (AD). Immunotherapy… (More)
Is this relevant?
Review
2014
Review
2014
PURPOSE OF REVIEW We reviewed clinical trials on active and passive anti-β-amyloid (Aβ) immunotherapy for the treatment of… (More)
Is this relevant?
Review
2014
Review
2014
Dementia is a public health priority and one of the major contributors to morbidity and global non-communicable disease burden… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer's… (More)
Is this relevant?
2012
2012
A previous phase II trial of another Aβ-targeted immunotherapy, AN1792, was suspended early as the treatment caused… (More)
Is this relevant?
Review
2012
Review
2012
As a neurodegenerative disorder, Alzheimer disease (AD) is the most common form of dementia found in the aging population… (More)
Is this relevant?
2011
2011
Immunization against amyloid-β (Aβ) can reduce amyloid accumulation in vivo and is considered a potential therapeutic approach… (More)
Is this relevant?
Review
2010
Review
2010
Vaccines targeting the amyloid-β (Aβ) peptide have promise as immunotherapies for the treatment of Alzheimer disease (AD). Human… (More)
Is this relevant?